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Noninvasive biomarkers are clinically useful for evaluating liver fibrosis stage in patients
with nonalcoholic fatty liver disease (NAFLD). The aim of the present study was to compare
plasma proteins in patients with early nonalcoholic steatohepatitis (NASH) (F0-F1) versus
NASH with significant/advanced fibrosis (F2–F4) to determine whether candidate proteins
could be used as potential noninvasive biomarkers. Nineteen biopsy-proven NAFLD patients
including ten early NASH patients and nine NASH patients with significant/advanced fibrosis
were enrolled in the present study. High-resolution proteomics screening of plasma was per-
formed with the SCIEX TripleTOF 5600 System. Proteins were quantified using two different
software platforms, Progenesis Qi and Scaffold Q+, respectively. Progenesis Qi analysis re-
sulted in the discovery of 277 proteins compared with 235 proteins in Scaffold Q+. Five con-
sensus proteins (i.e. Complement component C7; α-2-macroglobulin; Complement compo-
nent C8 γ chain; Fibulin-1; α-1-antichymotrypsin) were identified. Complement component
C7 was three-fold higher in the NASH group with significant/advanced fibrosis (F2–F4) com-
pared with the early NASH (F0-F1) group (q-value = 3.6E-6). Complement component C7
and Fibulin-1 are positively correlated with liver stiffness (P=0.000, P=0.002, respectively);
whereas, Complement component C8 γ chain is negatively correlated (P=0.009). High lev-
els of Complement C7 are associated with NASH with significant/advanced fibrosis and
Complement C7 is a perfect classifier of patients included in this pilot study. Further studies
will be needed in a larger validation cohort to confirm the utility of complement proteins as
biomarkers or mechanistic determinants of NASH with significant/advanced fibrosis.
Introduction
Nonalcoholic fatty liver disease (NAFLD), one of the most common liver diseases worldwide, can be cat-
egorized histologically into nonalcoholic fatty liver (NAFL) or nonalcoholic steatohepatitis (NASH) [1].
Accurately evaluating liver fibrosis stage in NAFLD patients is of importance for identifying those who
may progress to liver cirrhosis and hepatocellular carcinoma. Although a liver biopsy is the gold stan-
dard for diagnosing and determining the stages of fibrosis, there is an urgent need to develop noninvasive
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methods [2–12], including imaging modalities [13–17], biomarkers [18–26], and artificial intelligence algorithms
[27–32].
The purpose of the present study was to perform proteomic screening of plasma via SCIEX TripleTOF 5600 System
[33–35] to identify potential noninvasive biomarkers in NAFLD patients with significant/advanced liver fibrosis.
Methods
Patients
Plasma samples were acquired through the ‘Prevalence and Risk Factors for NAFLD in patients with T2DM’ study
conducted at the Royal London Hospital, Barts Health NHS Trust, United Kingdom (U.K.). The study was approved by
the National Research Ethic Service (Reference 14/WA/1142) and carried out in accordance with the World Medical
Association Declaration of Helsinki. Written informed consent was obtained from all participants.
Histological evaluation
All patients enrolled in the present study had undergone a percutaneous liver biopsy. Fibrosis stage was scored ac-
cording to the Kleiner classification [36] on a 5-point scale (F0–F4).
Clinical and biochemical data
Relevant clinical data were recorded, including the patients’ age, sex, weight, and height. Body mass index (BMI) was
calculated as weight (kg) divided by height (m) squared. Venous blood samples were collected in lithium-heparin
tubes and plasma was stored at −80◦C until analysis. Laboratory evaluation in all patients included measurement
of the serum levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT). Liver stiffness for all
patients were assessed by FibroScan.
Proteomics and data processing
Plasma was assayed for total protein (Bio-Rad Protein Assay) and 5 μl was digested with trypsin (1:10 ratio enzyme
to protein) for 18 h at 37◦C following following reduction and alkylation as we previously described [37]. Peptides
were desalted using solid phase extraction cartridges (Strata-x, Phenomenex) and eluted sequentially in 25% ace-
tonitrile/0.1% formic acid and 45% acetonitrile/0.1% formic acid. Each peptide fraction was diluted 1:4000 in 0.1%
formic acid and 10 μl injected on to a 2-cm c18 trap column (Dionex pepmap100, Thermo Scientific). Peptides were
separated on a c18 analytical column (15 cm × 75 μm, Dionex pepmap 100) for 60 min from 0.1% formic acid to
50% acetonitrile/0.1% formic acid. Data were acquired in IDA mode on a SCIEX 5600. Wiff files were uploaded to
Progenesis Qi or converted into .MGFs for MASCOT searching (v2.4) against the human proteome database (Swis-
sProt/UniProt; 2015) before being loaded to Scaffold Q+. Both Progenesis Qi and Scaffold Q+ were utilized to de-
termine significant protein differences to construct a consensus differential protein list to reduce analytical bias of a
single software platform. Proteomics data of the present study has been loaded into the ProteomeXchange database
(Submission Reference No.: 1-20190126-112361).
Statistical analysis
Statistical differences in Progenesis Qi were determined using ANOVA of log2 transformed data and P-values cor-
rected for local false discovery rate (q-value). Proteins with q-values less than 0.05 were considered different. Statis-
tical differences in Scaffold Q+ were determined using a t test of normalized spectral abundance factors (NSAF) as a
comparison with Progenesis Qi results. NSAF values were not transformed for normality, nor were P-values adjusted
for multiple comparisons. For statistically different proteins (Progenesis Qi), receiver operating characteristic (ROC)
curves were created in Sigmaplot plotted using the data from Progenesis Qi, and the areas under the ROC curves (AU-
ROCs) were calculated in order to represent classification performance. Correlation analysis was performed by using
the Pearson’s correlation coefficient test in SPSS (IBM). Differences were considered to be statistically significant at
P<0.05.
Results
Characteristics of NAFLD patients
A total of 19 biopsy-proven NAFLD patients were enrolled in the present study, including 10 early NASH patients
and 9 NASH patients with significant/advanced fibrosis. The characteristics of the patients are summarized in Table
1. There were no significant differences in terms of sex, age, BMI, ALT, AST and smoking between the two groups.
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Table 1 Clinical characteristics of the patients enrolled in the study
Early NASH (F0-1) Advanced NASH (F2–4) P-value
Sex (M/F) (4/6) (5/4) 0.65
Age (Mean [Range], Years) 55.6 [35–70] 58.4 [47–74] 0.56
BMI 31 +− 4 32 +− 4 0.38
Diabetes (No. Pts) 1 9 <0.001
Stiffness (kPa) 5.8 +−1.7 19.7 +− 9.8 <0.001
FIB4 1.1 +− 0.2 2.1 +−0.9 <0.01
ALT 44 +− 34 65 +− 29 0.34
AST 34 +− 20 51 +− 19 0.14
Smoker (%) 90% 89% 1
Table 2 Identification of five consensus proteins via Progenesis Qi and Scaffold Q+ analysis in NASH patients with
significant/advanced fibrosis versus early NASH patients
Protein name Progenesis Qi (total proteins = 277) Scaffold Q (total proteins = 235)
Complement component C7
α-2-macroglobulin
Complement component C8 γ chain
Fibulin-1 OS = Homo sapiens
α-1-antichymotrypsin
Patients with significant/advanced NASH fibrosis had elevated liver stiffness (P<0.001), Fibrosis-4 (FIB-4) score
(P<0.01), and a higher prevalence of diabetes (P<0.001).
Differentially abundant plasma proteins
Progenesis Qi workflow analysis resulted in the discovery of 277 proteins compared with 235 proteins in Scaffold
Q+ workflow. Five consensus proteins (i.e. Complement component C7; α-2-macroglobulin; Complement compo-
nent C8 γ chain; Fibulin-1; α-1-antichymotrypsin) were shown in Table 2. Hierarchal clustering of 17 significantly
different proteins from the Progenesis Qi workflow was utilized to group patients using an average (UPGMA) ag-
glomeration method in R Studio. Color intensity indicates standard deviations from the mean (Z-score) in a positive
(red) or negative (blue) direction (Figure 1). The volcano plot (log2 fold change vs. P-value) displays all proteins iden-
tified in the Progenesis Qi analysis (Figure 2). Complement component C7 was three-fold higher (log2 = 1.65) in the
NASH group (F2–F4) with significant/advanced fibrosis compared with the early NASH (F0-F1) group (q-value =
3.6E-6).
ROC curves
Classification performance was estimated using AUROCs for the five consensus different proteins identified. As
shown in Figure 3A, the AUROCs for those proteins elevated in NASH patients with significant/advanced fibro-
sis (F2–F4) are 1.00 (Complement component C7), 0.87 (α-2-macroglobulin), and 0.79 (Fibulin-1), respectively. As
shown in Figure 3B, the AUROCs for those proteins reduced in NASH patients with significant/advanced fibrosis
(F2–F4) are both 0.80 (Complement component C8 γ chain; α-1-antichymotrypsin).
Correlation analysis
As shown in Table 3, Complement component C7 and Fibulin-1 are positively correlated with liver stiffness (P=0.000,
P=0.002, respectively); whereas, Complement component C8 γ chain is negatively correlated (P=0.009). Moreover,
Complement C7 and α-2-macroglobulin were positively correlated with FIB-4 (P=0.031, P=0.042, respectively)
while Complement component C8 γ chain was negatively correlated with FIB-4 (P=0.013). Interestingly, Comple-
ment component C7 also positively correlated with HBA1c (P=0.045) while γ-1-antichymotrypsin is negatively cor-
related with ALT (P=0.036).
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 1. Hierarchal clustering heat map of significant plasma proteins as discovered by Progenesis Qi analysis
Hierarchal clustering of 17 significantly different proteins was utilized to group patients using an average (UPGMA) agglomeration
method in R Studio. Color intensity indicates standard deviations from the mean (Z-score) in a positive (red) or negative (blue)
direction.
Table 3 Pearson’s r correlation analysis of five consensus differential plasma proteins
Stiffness
Complement
C7
α-2-
macroglobulin
Complement
C8 γ chain Fibulin-1 α-1-antichymotrypsin
Stiffness Pearson correlation - 0.740† 0.407 −0.584† 0.657† −0.453
Sig. (two-tailed) - 0.000 0.084 0.009 0.002 0.051
n - 19 19 19 19 19
FIB-4 Pearson correlation 0.502 0.556* 0.530* −0.623* 0.297 −0.330
Sig. (two-tailed) 0.056 0.031 0.042 0.013 0.282 0.230
n 15 15 15 15 15 15
ALT Pearson correlation 0.126 0.037 0.185 −0.459 0.320 −0.511*
Sig. (two-tailed) 0.629 0.887 0.477 0.064 0.210 0.036
n 17 17 17 17 17 17
HBA1c Pearson correlation 0.539 0.613* 0.438 −0.077 0.010 0.068
Sig. (two-tailed) 0.087 0.045 0.178 0.821 0.977 0.843
n 11 11 11 11 11 11
BMI Pearson Correlation 0.277 0.228 0.264 −0.167 0.267 0.072
Sig. (two-tailed) 0.251 0.347 0.274 0.494 0.270 0.770
N 19 19 19 19 19 19
*Correlation is significant at the 0.05 level (two-tailed).
†Correlation is significant at the 0.01 level (two-tailed).
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Figure 2. The volcano plot of all proteins identified in the Progenesis Qi analysis
Complement C7 was circled above and was three-fold higher (log2 = 1.65) in the NASH group with significant/advanced fibrosis
(F2–F4) compared with the early NASH (F0-F1) group (actual q-value = 3.6E-6, but was changed to 0.0001 for display purposes).
Discussion
The present study showed for the first time that Complement C7 and C8 γ chain and Fibulin-1 significantly correlate
with liver stiffness. Moreover, Complement C7 acted as a potential biomarker to identify those NASH patients with
significant/advanced liver fibrosis.
The complement system, a phylogenetically ancient makeup of the humoral system, consisting of a cascade of
proteases and soluble factors, plays a vital role in innate immune [38]. The role of complement in liver diseases is less
well characterized. The complement components C3 and C5 were reported to be associated with NAFLD [39–41]
and C5 had a causal role in liver fibrogenesis [42]. There are strong and persistent stimuli for complement activation
in NAFLD through multiple pathways, including the classical pathway and the lectin pathway [43], as well as the
alternative pathway [44]. The complement component 7 (C7) is a terminal component of the complement cascade.
The role C7 plays in the pathogenesis and progression of NAFLD are largely unknown. Our results showed that
C7 was three-fold higher in the NASH group with significant/advanced fibrosis (F2–F4) compared with the early
NASH (F0-F1) group, consistent with previous studies [45], suggesting C7 might be an important contributor in the
pathogenesis of NAFLD. The exact mechanisms of C7 in the progress of NAFLD need to be further elucidated.
One limitation of our pilot study is the relatively small number of patients. Nevertheless, the sample numbers
were sufficient to show significant differences in plasma proteins between early NASH and NASH with signifi-
cant/advanced fibrosis in a conceptual approach.
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 3. Classification performance estimated using ROC curve for the five consensus differential plasma proteins
(A) Proteins elevated in the NASH patients with significant/advanced fibrosis (F2–F4). (B) Proteins lower in the NASH patients with
significant/advanced fibrosis (F2–F4). Abbreviation: AUC, area under the curve. All areas have a P-value <0.03.
In summary, the present study demonstrated that Complement C7 and C8 γ chain as well as Fibulin-1 signifi-
cantly correlated with liver stiffness. Elevated levels of Complement C7 were detected in NASH patients with signifi-
cant/advanced fibrosis and were a perfect classifier for patients included in this pilot study. Further studies in a larger
validation cohort will be needed to confirm the utility of complement proteins as potential biomarkers or mechanistic
determinants of progressive NASH.
Perspectives
• Accurately evaluating liver fibrosis stage in NAFLD is important because it enables the identification
of those most likely to progress to liver cirrhosis and hepatocellular carcinoma. Although a liver biopsy
remains the current gold standard for diagnosis and staging of liver disease, it is invasive, costly, and
with inherent risks; hence there is an urgent need to develop noninvasive methods.
• Proteomic screening of plasma via SCIEX TripleTOF 5600 System identified potential noninvasive
biomarkers of NAFLD patients with significant/advanced liver fibrosis. Complement components C7
and C8 γ chain, and Fibulin-1 significantly correlated with liver stiffness.
• In this pilot, high levels of Complement C7 were associated with NASH with significant/advanced
fibrosis and Complement C7 is a perfect classifier of patients with NASH.
Competing Interests
The authors declare that there are no competing interests associated with the manuscript.
6 © 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons
Attribution License 4.0 (CC BY).
Bioscience Reports (2020) 40 BSR20190395
https://doi.org/10.1042/BSR20190395
Funding
This work was supported in part by the Office of Naval Research [grant number N000141410361 (to M.G.J.)]; the Division of
Gastroenterology and Hepatology and Division of Nephrology Funds [(to W.-K.S.), (to M.G.J.)]; the Ralph H. Johnson VAMC [(to
W.-K.S.)]; and the Diabetes Research and Wellness Fund [(to W.A. and W.-K.S.)].
Author Contribution
W.-K.S. and M.G.J. conceived and designed the study. W.H., M.G.J., P.S., A.B., W.-K.S. performed data collection and analysis,
and contributed to drafting of the manuscript. S.S. and W.A. provided technical and material support. W.H., M.G.J., W.A. and
W.-K.S. contributed to critical revision of the manuscript. All authors approved the final version of the manuscript.
Abbreviations
ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUROC, area under the ROC curve; BMI, body mass index;
FIB-4, Fibrosis-4; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; NSAF, normalized spectral
abundance factor; ROC, receiver operating characteristic.
References
1 Chalasani, N., Younossi, Z., Lavine, J.E., Charlton, M., Cusi, K., Rinella, M. et al. (2018) The diagnosis and management of nonalcoholic fatty liver
disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67, 328–357,
https://doi.org/10.1002/hep.29367
2 Brunt, E.M., Wong, V.W., Nobili, V., Day, C.P., Sookoian, S., Maher, J.J. et al. (2015) Nonalcoholic fatty liver disease. Nat. Rev. Dis. Primers 1, 15080,
https://doi.org/10.1038/nrdp.2015.80
3 Rinella, M.E. (2015) Nonalcoholic fatty liver disease: a systematic review. JAMA 313, 2263–2273, https://doi.org/10.1001/jama.2015.5370
4 Cheah, M.C., McCullough, A.J. and Goh, G.B. (2017) Current modalities of fibrosis assessment in non-alcoholic fatty liver disease. J. Clin. Transl.
Hepatol. 5, 261–271
5 Tapper, E.B. and Lok, A.S. (2017) Use of liver imaging and biopsy in clinical practice. N. Engl. J. Med. 377, 756–768,
https://doi.org/10.1056/NEJMra1610570
6 Bellan, M., Castello, L.M. and Pirisi, M. (2018) Candidate biomarkers of liver fibrosis: a concise, pathophysiology-oriented review. J. Clin. Transl.
Hepatol. 6, 317–325
7 Schuppan, D., Surabattula, R. and Wang, X.Y. (2018) Determinants of fibrosis progression and regression in NASH. J. Hepatol. 68, 238–250,
https://doi.org/10.1016/j.jhep.2017.11.012
8 Tsai, E. and Lee, T.P. (2018) Diagnosis and evaluation of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis, including noninvasive biomarkers
and transient elastography. Clin. Liver Dis. 22, 73–92, https://doi.org/10.1016/j.cld.2017.08.004
9 Vilar-Gomez, E. and Chalasani, N. (2018) Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based
biomarkers. J. Hepatol. 68, 305–315, https://doi.org/10.1016/j.jhep.2017.11.013
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